The purpose of this study is to attempt to eliminate the necessity of immunosuppressive therapy for HLA-identical sibling Kidney Transplants, examine cellular chimerism of donor hematopoietic stem cell (DHSC) lineages for pairs to demonstrate immunologic unresponsiveness, and to investigate the safety and efficacy of the treatment regimen including withdrawal of immunosuppression after one year post-transplant for those recipients having received DHSC infusions.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient fully informed, signed dated Institutional Review Board (IRB)-approved informed consent form obtained directly by the P.I., Co-P.I., or Res. Nurse, and willing to follow study procedures for the duration of study (3 yrs).
* Recipient: a hematocrit of ≥ 33%, and a hemoglobin of ≥ 11.0 g/dL.
* Weight \> 40 kg.
* Primary renal allograft: living related (HLA-identical donor-recipient sibling pairs)
* Negative B-cell and T-cell cytotoxic cross-match, and a low (≤ 10%) Panel Reactive Antibody (PRA) using cytotoxicity.
* Women of childbearing potential: negative qualitative serum pregnancy test.
* Patients studied equivalently as available for transplant using criteria, w/out regard to gender, race, or ethnicity.
* Normal echocardiogram w/ ejection fraction \>50%.
* Male participants w/ reproductive potential agree to use approved methods of birth control during treatment w/ Campath-1H and for minimum of 6 months following last dose. Female participants of childbearing potential agree to use approved methods of birth control for duration of participation in study.
* Patient agrees to follow-up every 2 months after year 3, up to 10 years.
Exclusion Criteria:
* Patient previously received/receiving transplant other than kidney.
* Patient receiving ABO (blood type) incompatible donor kidney.
* Recipient/donor is ELISA positive for human immunodeficiency virus (HIV), antibody positive for hep. C, or surface antigen positive for hep. B.
* Patient has curr…
What they're measuring
1
The Ability to Withdraw Immunosuppression as Above 24 Months Post-transplant
Timeframe: 24 months post-transplant with follow-up to 10 years